Adenia takes majority stake in Parkville to scale Egyptian pharma

Adenia Partners has agreed to acquire a majority stake in Parkville Pharmaceuticals, marking the private equity firm’s inaugural investment in Egypt. The transaction, announced from Cairo, moves a locally built healthcare and personal-care champion into the hands of a new long-term growth investor; financial terms were not disclosed and the deal remains subject to regulatory approvals.

Parkville Pharmaceuticals, founded in 2008 and headquartered in Cairo, manufactures and markets an array of pharmaceutical, nutraceutical and cosmeceutical products including skincare, haircare, deodorants and wellness lines. Over the last decade the group has positioned itself as a strong domestic competitor, combining manufacturing capability with an expanding R&D and brand portfolio.

The sellers include the current private equity backer Admaius Capital Partners alongside company founders and executives led by Dr. Sherif Bassiouny (Chairman) and Dr. Mahmoud Farrag (CEO). Adenia has said it will partner with the founders and management to accelerate product development, upgrade commercial and digital channels and drive a phased rollout into neighbouring markets across MENA and sub‑Saharan Africa.

Strategically, the transaction lands at a time when Egypt’s healthcare and consumer-health sectors are drawing sustained investor interest. The Egyptian pharmaceutical market is widely viewed as one of the largest in the region — commonly estimated around several billion dollars — supported by stable domestic demand, a growing middle class and rising private consumption of personal-care products. The cosmeceutical and nutraceutical segments, in particular, are recording above-market growth as digital penetration and pharmacy retail modernisation increase.

Stéphane Bacquaert, Managing Partner at Adenia Partners, described the acquisition as a foothold to back an Egypt‑built platform with regional potential. Heba Hakky, Principal at Adenia, said the firm sees opportunity in scaling Parkville’s direct-to-consumer and e‑commerce efforts — channels that are gaining share in MENA beauty and wellness sales.

For Parkville, the partnership with Adenia is pitched as a move to professionalise functions that matter for a regional roll‑out: bolstering R&D, expanding higher‑margin branded lines, and investing in digital marketing and distribution. Management pointed to the transformation achieved under Admaius’ stewardship and framed the change of ownership as a step towards becoming a Middle East and Africa contender.

From a market perspective, the deal underlines two trends: private equity appetite for resilient consumer-health platforms in North Africa, and a broader push to convert manufacturing-led local champions into exportable, brand-led businesses. Potential exit routes for Adenia could include trade sale to a multinational consumer-health group, regional private equity syndication or a public-market listing, depending on growth execution and valuation momentum.

Advisors on the transaction included law firm Baker McKenzie for Adenia Partners, with Zilla Capital acting for the selling shareholders and Matouk Bassiouny providing legal counsel to the sellers.